Dissecting the early steps of MLL induced leukaemogenic transformation using a mouse model of AML
The oncogene MLL is frequently translocated in leukemia, resulting in oncogenic fusion proteins. Here, the authors report a temporally controlled mouse model of MLL-ENL driven leukemia AND identify therapeutic targets associated with early MLL-ENL driven leukaemogenesis.
Guardado en:
Autores principales: | Silvia Basilico, Xiaonan Wang, Alison Kennedy, Konstantinos Tzelepis, George Giotopoulos, Sarah J. Kinston, Pedro M. Quiros, Kim Wong, David J. Adams, Larissa S. Carnevalli, Brian J. P. Huntly, George S. Vassiliou, Fernando J. Calero-Nieto, Berthold Göttgens |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f3f11e1f04f14988aa6abc97b3c99275 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
FOXM1 regulates leukemia stem cell quiescence and survival in MLL-rearranged AML
por: Yue Sheng, et al.
Publicado: (2020) -
Selective binding of the PHD6 finger of MLL4 to histone H4K16ac links MLL4 and MOF
por: Yi Zhang, et al.
Publicado: (2019) -
TARGETED THERAPY IN AML TREATMENT
por: Giovanni Martinelli
Publicado: (2021) -
MLL2 is required in oocytes for bulk histone 3 lysine 4 trimethylation and transcriptional silencing.
por: Claudia V Andreu-Vieyra, et al.
Publicado: (2010) -
AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin.
por: David B Rosen, et al.
Publicado: (2013)